Fluoxetine (Prozac) is More Activating Than Vortioxetine (Trintellix)
Fluoxetine is classified as an "activating" SSRI, while vortioxetine is not specifically characterized as activating in the available evidence. Based on guideline-level evidence, fluoxetine is explicitly described as "activating" with recommendations to give the second dose before 3 p.m. to minimize insomnia risk 1. In contrast, vortioxetine's FDA label and clinical studies do not characterize it as having activating properties 2.
Evidence Supporting Fluoxetine's Activating Profile
The 2002 Alzheimer's Disease Management Guidelines explicitly categorize fluoxetine as "activating, very long half-life" among SSRIs 1. This same guideline notes that bupropion is "activating" with "possible rapid improvement of energy level" and should not be used in agitated patients 1. Fluoxetine shares this activating characteristic, though to a lesser degree than bupropion.
The 2008 American College of Physicians guidelines note that fluoxetine and sertraline had similar efficacy in patients with psychomotor retardation, but sertraline performed better in patients with psychomotor agitation 3. This suggests fluoxetine may worsen agitation in some patients, consistent with an activating profile.
Vortioxetine's Side Effect Profile
Vortioxetine's mechanism involves multimodal serotonergic activity beyond simple reuptake inhibition 2. The FDA label lists common adverse effects as nausea, constipation, and vomiting—not the insomnia, nervousness, or agitation typically associated with activating antidepressants 2.
Clinical trials show vortioxetine's most common side effects are gastrointestinal (nausea, vomiting, constipation) rather than CNS-activating symptoms 4, 5, 6. A 2016 comparative analysis found vortioxetine had favorable tolerability with an NNH of 43 for discontinuation due to adverse events, better than most comparators 7.
Clinical Implications
If you need an activating antidepressant to combat apathy or low energy, choose fluoxetine over vortioxetine. Fluoxetine's activating properties make it suitable for patients with psychomotor retardation or low energy 1. However, avoid fluoxetine in patients with:
- Significant anxiety or agitation
- Insomnia (give second dose before 3 p.m. if used) 1
- Psychomotor agitation (consider sertraline instead) 3
Vortioxetine is better suited for patients who cannot tolerate activating effects or those with comorbid anxiety, as it demonstrated efficacy in MDD patients with high anxiety symptoms (HAM-A ≥20) without causing activation 8. Recent evidence shows vortioxetine achieved higher CGI-S remission rates than desvenlafaxine in SSRI partial responders, with better functional outcomes 9.
Common Pitfall to Avoid
Don't assume all SSRIs are equally activating. Among SSRIs, paroxetine is explicitly "less activating but more anticholinergic" than other SSRIs 1. The activation spectrum runs: bupropion (most activating) > fluoxetine > sertraline > paroxetine (least activating among those listed) 1.